Philip Morris International (PM) stock has gone practically nowhere for the past year, but Goldman Sachs sees that changing. The firm just reiterated a $205 base-case price target, implying about 33% upside from the stock’s current price near $153.
The call comes down to one idea. Philip Morris is no longer just a cigarette company; it is becoming a smoke-free business. That shift could drive a higher-quality earnings profile if execution holds.
Goldman Sachs sees 33% upside as smoke-free products drive the story
Goldman Sachs is making a clear call on Philip Morris. The firm has reiterated its $205 base-case price target for the stock, implying about 33% upside from the stock’s current price of roughly $153.
That view is built on one core shift: Philip Morris is becoming a smoke-free business. New segment reporting separates International Smoke-Free from combustibles, making it easier to see where growth and profit are coming from.
Related: Popular vodka brand closes facility, leases to rival distillery
As analyst Bonnie Herzog said, “We continue to see a pathway for strong top- and bottom-line growth over the next several years, given the compounding effect of IQOS and opportunities with ZYN…PM is transforming into a faster-growing and more profitable business – an earnings compounder with an attractive valuation.”
Smoke-free products now account for over 40% of total revenue, and international smoke-free is expected to grow from 34% in 2025 to 39.5% by 2028. That shift means a larger share of results will come from categories that are still adding users, taking price, and leveraging fixed costs.
That changes how the stock is valued. Philip Morris is no longer judged mainly as a cigarette company, but that re-rating depends on whether smoke-free growth translates into durable profit. Philip Morris is guiding to 11.1-13.1% EPS growth in 2026, and analysts have pointed to improved visibility as a driver of upside.
ZYN slowdown is the main near-term risk
The clearest near-term risk to that story is the sharp deceleration in U.S. ZYN growth. Q1 U.S. ZYN volume growth is estimated at just 2.5%, down sharply from 19.3% in Q4. Full-year 2026 U.S. ZYN growth is forecast at 14.1%, versus 36.7% growth that Zyn saw for 2025. That is a meaningful slowdown for a product that has been central to Philip Morris’s U.S. reduced-risk momentum.
The key question is whether this is a timing issue or something more structural. Temporary factors like retailer de-stocking or promotional timing would mainly shift revenue between quarters.
Top Investing News:
- JPMorgan resets S&P 500 price target for the rest of 2026
- Michael Burry drops shocking verdict on software stocks
- Robert Kiyosaki says only 6 assets will survive 2026
A more sustained slowdown would raise concerns about demand, competition, and the durability of ZYN’s growth trajectory.
ZYN plays a central role in the company’s broader transition toward smoke-free products, particularly in the U.S. market. A quick rebound would support confidence in that strategy, while continued weakness would put pressure on assumptions around mix improvement, operating leverage, and the stock’s valuation.
Margin expansion remains huge for 2026
Even if smoke-free growth slows, Philip Morris still has another key earnings lever: margin expansion.
Analysts estimate FY26 operating margin at 41.3%, supported by product mix, pricing, first-quarter FX tailwinds, and roughly $500 million in planned cost savings. That only matters if those benefits actually show up in operating profit.
J2R via Getty Images
Philip Morris can support a premium valuation if it keeps margins in the low-40% range while delivering double-digit earnings growth, even with weaker U.S. ZYN trends.
That would show the business does not rely on a single product or category.
What could drive $PM shares higher
- Continued smoke-free mix expansion, with revenue staying above 40% and International Smoke-Free gaining share.
- Strong profitability from IQOS and other smoke-free products, proving the mix shift improves earnings quality.
- Execution on roughly $500 million in cost savings flowing through to profit.
- Pricing power offsetting any volume pressure.
- A rebound in U.S. ZYN trends after early-year disruption.
What could pressure Philip Morris stock
- Prolonged weakness in U.S. ZYN volume.
- Slower-than-expected realization of cost savings.
- FX benefits boosting revenue more than underlying earnings.
- Increased competition in oral nicotine or heated tobacco markets.
Philip Morris key takeaway
Goldman Sachs sees meaningful upside in Philip Morris as smoke-free products drive growth, but the bull case depends on margin execution and a rebound in ZYN.
Related: 179-year-old tobacco giant sends blunt message to workers
